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Pulmonary arterial hypertension (PAH) is a rare and severe clinical
condition characterized by a progressive increase of pulmonary
vascular resistance leading to right ventricular failure and prema-
ture death (Figure 1).
1 Its prevalence ranges from 15 to 50 patients
per million population
2,3 and it affects a relatively young patient
population (average age of 50 years) when compared with the
more common thoracic organ diseases such as coronary artery
disease and chronic obstructive lung disease. PAH in adults
includes at least nine clinical subgroups with virtually identical
obstructive pathologic changes (Figures 1 and 2) in the distal pul-
monary arteries: idiopathic, heritable, drug- and toxin-induced,
associated with, connective tissue diseases, HIV infection, portal
hypertension, congenital heart disease, schistosomiasis, and
chronic haemolytic anaemia.
1
Pathogenesis
1
The exact processes that initiate the pathological changes seen in
PAH are largely unknown. It is hypothesized that the interaction
between genetic predisposition and environmental risk factors
(Figure 1) may be involved in the initial stages of the disease.
However, even the exact role of the auto-antibodies in connective
tissue diseases or the viral involvement in HIV infection is unclear.
It appears that a speciﬁc injury on the vessel wall of distal pulmon-
ary arteries may initiate, in predisposed individuals, a pathobiologi-
cal cascade of events which leads to a common ﬁnal pathological
obstructive condition (Figures 1B and C and 2). In the initial
phases of these processes, the disease is asymptomatic, and detect-
able pathophysiological changes and symptoms limiting exercise
capacity appear usually when the pathological lesions are fully
developed (Figure 1).
Pathology
4,5
Pathological lesions in PAH patients affect the distal pulmonary
arteries (,500 mm), in particular. The lesions are characterized
by medial hypertrophy, intimal proliferative and ﬁbrotic changes
(concentric and/or eccentric), adventitial thickening with moderate
peri-vascular inﬂammatory inﬁltrates (Figures 1B and C and 2),
complex lesions (plexiform, dilated), and thrombotic lesion.
Pathobiology
6–8
The pathobiology of the distal pulmonary arteries in PAH patients
is multifactorial and involves various biochemical pathways and cell
types (Figure 2). Excessive vasoconstriction has been related to
abnormal function or expression of potassium channels in the
smooth muscle cells and to endothelial dysfunction. Endothelial
dysfunction leads to chronically impaired production of vasodilator
and antiproliferative agents such as nitric oxide and prostacyclin,
along with over-expression of vasoconstrictor and proliferative
substances such as thromboxane A2 and endothelin. Many of
these abnormalities both elevate vascular tone and promote vascu-
lar remodelling by proliferative changes that involve several cell
types, including endothelial and smooth muscle cells as well as
ﬁbroblasts. In addition, in the adventitia, there is increased pro-
duction of extracellular matrix including collagen, elastin, and ﬁbro-
nectin and of matrix-bound smooth muscle cell mitogens, such as
basic ﬁbroblast growth factor. Other matrix metalloproteases can
stimulate the production of tenascin, a smooth muscle cell mito-
genic cofactor. Several additional growth factors including vascular
endothelial growth factor, platelet-derived growth factor, insulin-
like growth factor-1, and epidermal growth factor have been impli-
cated in the development of remodelling and all have been
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doi:10.1093/eurheartj/ehq152reported to be increased (the molecule and/or the speciﬁc recep-
tors) in the lung and/or in the blood of PAH patients. Reduced
plasma levels of other vasodilator and antiproliferative substances
such as vasoactive intestinal peptide have also been demonstrated.
Angiopoietin-1, an angiogenic factor essential for vascular lung
development, seems to be up-regulated in cases of PAH correlat-
ing directly with the severity of the disease. Receptors of the bone
morphogenetic protein pathway, involved in cellular proliferation
and apoptosis, are down-regulated and/or malfunctioning in the
lung vasculature of both heritable and acquired PAH. Inﬂammatory
cells, cyto- and chemokines, and platelets (through the serotonin
pathway) may also play a signiﬁcant role in PAH. Prothrombotic
abnormalities have been demonstrated in PAH patients and
thrombi are present in both the small distal pulmonary arteries
and in proximal elastic pulmonary arteries.
Pathophysiology
9,10
The increase of pulmonary vascular resistance in PAH patients
is therefore related to different mechanisms, including vasocon-
striction, proliferative and obstructive remodelling of the pulmon-
ary vessel wall, inﬂammation, and thrombosis (Figure 2).
Vasoconstriction is likely prevalent in the small group of patients
responding to the acute vasoreactivity test.
1
The increase in pulmonary vascular resistance leads to right
ventricular overload, hypertrophy, and dilatation and eventually
Figure 1 Schematic representation of pathogenesis, pathology, pathophysiology, and symptoms in pulmonary arterial hypertension. (A)N o r m a l
small distal pulmonary artery: the thin wall is constituted by a single elastic lamina and a thin layer of smooth muscle cells; a large lumen with red
blood cells is also shown. (B) Distal pulmonary artery in pulmonary arterial hypertension: increased thickness of the media due to hypertrophy and
hyperplasia of smooth muscle cells and moderate lumen reduction are present. This picture may represent an initial phase of the disease and/or the
prevalent changes in patients responding to vasoreactivity tests. (C) Distal pulmonary artery in pulmonary arterial hypertension: increased thickness
of the media and also of the intima due to proliferation/migration of myoﬁbroblasts and ﬁbrosis are present. Severe lumen reduction is also shown.
This picture may represent an advanced phase of the disease and/or the prevalent changes in patients not responding to vasoreactivity tests. (D)
Echocardiographic four-chamber view in pulmonary arterial hypertension: Severe dilatation of the right atrium and ventricle and reduction in size
of the left ventricle are shown. ALK1, activin-like kinase-type 1 gene; BNP, brain natriuretic peptide; BMPR2, bone morphogenetic protein receptor
type 2 gene; CHA, chronic haemolytic anaemia; CHD, congenital heart disease; CTD, connective tissue diseases; ENG, endoglin gene; HIV, human
immunodeﬁciency virus; CMR, cardiac magnetic resonance; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; WHO,
world health organization. The pathological pictures are a courtesy of Dr Carol Farver, Cleveland Clinic.
Pulmonary arterial hypertension 2081to right ventricle failure and death (Figure 1). The importance of
the progression of right ventricle failure on the symptoms, exer-
cise limitation, and outcome of PAH patients is conﬁrmed by the
prognostic impact of right atrial pressure, cardiac index and pul-
monary arterial pressure, the three main haemodynamic factors
linked to right ventricle pump function. Echocardiography and
cardiac magnetic resonance parameters and brain natriuretic
peptide plasma levels can also identify non-invasively the presence
and extent of right ventricular dysfunction (Figure 1). Afterload
mismatch remains the leading determinant of right heart failure
in patients with PAH because its removal, as follows lung trans-
plantation, leads almost invariably to sustained recovery of right
ventricle function. It is, therefore, conceivable that the drug thera-
pies tested in PAH patients have included compounds which
could potentially interfere with the pathobiological mechanisms
of the disease trying to achieve a reverse remodelling of the
obstructive lesions and a reduction of the right ventricular after-
load (Figure 2).
Progress of medical treatment in
pulmonary arterial hypertension
Two decades ago, patients with idiopathic PAH were deﬁned as
the ‘kingdom of the near-dead’
11 to outline their dismal median
survival rate that, at that time, was 2.8 years from the diagnosis,
9
despite any available supportive treatment. Usually, rare and
severe conditions are neglected by both the medical community
and the pharmaceutical industry due to the intrinsic difﬁculties of
performing experimental and clinical research in these ﬁelds. In
fact, meaningful randomized controlled trials (RCTs) in these set-
tings require a worldwide collaboration of expert centres operat-
ing with a similar standard of medical care and relatively large
Figure 2 Obstructive remodelling of a small pulmonary artery in pulmonary arterial hypertension (increased thickness of the three vessel
layers and severe lumen reduction are shown) and ongoing pathobiological processes in the different layers of the vessel wall (yellow
boxes) and in the blood. Asterisks indicate the potential processes involved. Corrective interactions of the related approved therapeutic inter-
ventions are also reported (green boxes). *Vasoconstriction;
†Proliferation/migration;
‡Inﬂammation;
§Thrombosis. B-FGF, basic ﬁbroblast
growth factor; BMPR, bone morphogenetic protein receptor; [Ca
2+], intracellular calcium concentration; K
+ch, membrane potassium channels;
SMC, smooth muscle cells; MFB, myoﬁbroblasts; MMP, matrix metalloproteases; PDE-5, phosphodiesterase type 5; PDGF, platelet-derived
growth factor; TxA2, tromboxane A2; VEGF, vascular endothelial growth factor; VIP, vasoactive intestinal peptide. The pathological picture
is a courtesy of Dr Carol Farver, Cleveland Clinic.
N. Galie ` et al. 2082ﬁnancial resources with a rather high risk of study failure. The
recent history of drug development in PAH contradicts this tra-
ditional perspective and it is worthwhile to analyse the details of
this phenomenon.
Without a doubt, the progress made in the medical treatment of
PAH in the past 15 years is unique, particularly for a rare and
severe condition: almost 30 RCTs have been completed and
more than 10 are either ongoing or planned. Twenty-ﬁve RCTs
have been published as of May 2010 (Figure 3). Eight drugs (ambri-
sentan, bosentan, epoprostenol, iloprost, sildenaﬁl, sitaxentan,
tadalaﬁl, treprostinil) belonging to three pharmacological classes
(endothelin receptor antagonists, phosphodiesterase type-5 inhibi-
tors, and prostanoids) administered by four different routes (oral,
inhaled, subcutaneous, and intravenous) have been currently
approved by the Food and Drug Administration (FDA) and/or by
the European Medicines Agency (EMA). All three classes of
drugs exert both vasodilator and antiproliferative effects and inter-
fere with the endothelial dysfunction abnormalities observed in
PAH patients (Figure 2).
Traditional endpoints for clinical
trials in pulmonary arterial
hypertension
The traditional primary endpoint of the RCTs performed in PAH
has been the 6 min walk test (6MWT)
12 that assesses the exercise
capacity, and secondary endpoints have included haemodynamics
and time to clinical worsening (TtCW), a composite endpoint
including death, hospitalization, and disease progression.
13,14
Based on the primary endpoint, the speciﬁc labelling indication
of all approved medications for PAH usually includes the
wording ‘to improve exercise capacity’ followed by the functional
classes of the patient population enrolled in the studies. This
reﬂects the fact that both regulatory agencies and investigators
agree that in rare and severe conditions dramatically impairing
the functional capacity of relatively young patients, exercise
capacity improvement can be considered a worthwhile initial
objective. In addition, the usual concordant favourable changes in
haemodynamics
12 and TtCW
13,14 observed in some studies
reinforced the results of the 6MWT. The use of this test as a
primary endpoint has allowed reasonable study sample sizes
(from 100 to 500 patients)
12 and randomized study duration
(from 2 to 6 months),
12 which are favourable feasibility character-
istics in a rare and severe disease. On the other hand, these same
characteristics have prevented the observation of effects on the
mortality rate except for studies enrolling the most severe
patient population.
15,16
Meta-analyses to assess the effect
on mortality
Meta-analysis of multiple studies is a technique that may allow the
analysis of parameters or events with a larger sample size and
with additional statistical insights. This approach requires the
inclusion of homogeneous studies as far as disease aetiology
and study designs are concerned. A ﬁrst meta-analysis on 16
RCTs performed in PAH
17 concluded that the treatments ‘pro-
duced limited beneﬁts in clinical end-points and failed to
support a signiﬁcant survival advantage’. However, the
meta-analysis included both acute and long-term studies and
one study on patients with lung ﬁbrosis and did not consider
six RCTs published before its submission. We performed a
second meta-analysis on 23 RCTs
12 in 3199 PAH patients pub-
lished as of October 2008. This analysis showed a reduction in
mortality ranging between 38 and 43% (according to different
inclusion criteria) after an average treatment period of 14.3
weeks. A subgroup analysis showed that all three classes of
PAH-approved drugs achieved a similar favourable reduction in
Figure 3 Time-course of 25 published randomized controlled studies (identiﬁed by acronyms, if any, or drug and year of publication) in pul-
monary arterial hypertension as of May 2010. Colour code identiﬁes the design of the study: monotherapy (black): investigational drug vs.
placebo in patients naive for pulmonary arterial hypertension approved drugs. Monotherapy and/or sequential combination (red): investigational
drug vs. placebo in patients either naive for, or treated with pulmonary arterial hypertension approved drugs. Upfront combination (light blue):
single drug vs. combination of two drugs in patients naive for pulmonary arterial hypertension approved drugs.
Pulmonary arterial hypertension 2083mortality, although no statistical signiﬁcance was achieved indivi-
dually. Updating our meta-analysis with two recently published
studies,
18,19 the overall reduction in mortality has been conﬁrmed
(Figure 4). These data have recently been validated by the authors
of the ﬁrst meta-analysis, who reported a reduction in mortality
of 39%, analysing the data of 3363 patients.
20 The concordance of
these results suggests, therefore, an improvement of survival in
patients treated with the targeted therapies currently approved
for PAH. The limitations of this conclusion include the short dur-
ation of the RCTs whose primary endpoint was not mortality and
the lack of evidence of a favourable long-term effect.
Nevertheless, we disagree with the opinion that the above limit-
ations are the key factors which should induce us to adopt new
trial designs, new endpoints, and longer durations of the RCTs.
20
Figure 4 Meta-analysis of published randomized controlled studies (identiﬁed by ﬁrst author and year of publication) in pulmonary arterial
hypertension as of May 2010. The primary analysis has included 3780 patients of 23 trials. The ﬁgure shows the cumulative RR estimate of death
in active treatment groups when compared with control groups stratiﬁed according to treatment class (inverse variance method). Studies with
no events in both groups were excluded. An overall reduction of mortality of 44% (P ¼ 0.016) is shown. The sensitivity analysis, including two
additional studies (59 patients) in which two treatment strategies were compared, conﬁrmed a reduction in mortality of 39% (P ¼ 0.041). The
subgroup analysis of the three classes of approved drugs achieved a similar favourable reduction in mortality, although no statistical signiﬁcance
was achieved individually. RR, relative risk. Modiﬁed from Galie ` et al.
12
N. Galie ` et al. 2084Given the higher mortality observed in the placebo groups of the
more recent meta-analyses
12,20 on PAH trials and the higher rate
of clinical deterioration observed in placebo-treated groups of indi-
vidual PAH studies,
15,16,18,21–25 it is not ethical, in our view, to
repeat RCTs in naı ¨ve PAH patients in order to satisfy the scientiﬁc
curiosity of ‘desk trialists’.
The way forward
The true issues PAH patients and physicians face in the clinical
practice is the insufﬁcient efﬁcacy of the present therapeutic
resources, despite clear progress and the escape from ‘the
kingdom of the near-dead’. The current treatment strategy, opti-
mized in recent guidelines,
1 remains inadequate because the mor-
tality rate continues to be high and the functional and
haemodynamic impairments are still extensive in many patients.
The speciﬁc drugs approved for PAH are able to slow the pro-
gression of the disease but cannot be considered a cure for the
majority of patients.
Current and future plans devoted to increasing our ability to
treat PAH are facing new challenges which require scientiﬁc crea-
tivity and new research strategies. Possible working hypotheses
include the drug combination approach and new candidate
classes of drugs.
Combination therapy
The rationale for combining approved PAH compounds is related
to the different pathobiological pathways targeted by the three
classes of approved PAH drugs (Figure 2). This combined approach
has successfully been employed in the treatment of other serious
and chronic diseases such as congestive heart failure, HIV infection,
and cancer. Combination therapy is currently recommended in
PAH patients with suboptimal response to the initial monotherapy
as an add-on with a compound of an alternative drug class (sequen-
tial combination therapy).
1 Different RCTs have currently shown
the efﬁcacy of this strategy on the improvement of exercise
capacity
16,18,19,21,26 and the reduction of TtCW.
16,18,26
An emerging concept relates to the use of ﬁrst-line combination
therapy with two drugs in PAH patients when compared with the
initial monotherapy. This hypothesis was tested in the BREATHE-2
trial, but the small sample size of the study did not allow for a
deﬁnitive conclusion.
27 The appropriate design to assess the efﬁ-
cacy of this strategy appears to be a three-arm study, comparing
combination therapy with two arms of monotherapy, using the
single compounds.
New candidate classes of drugs
Paradoxically, there is no shortage of novel candidate therapies for
PAH, including drugs, gene, and/or stem-cell treatments. These
approaches are intended to address alternative pathobiological
pathways (Figure 2) or explore new strategies such as regenerative
medicine. New drugs with ongoing or planned phase III studies in
this ﬁeld include oral compounds such as NO-independent stimu-
lators and activators of cyclic guanosine monophosphate, tyrosine
kinase inhibitors (platelet-derived growth factor inhibitors), tissular
dual endothelin receptor antagonists, prostanoids and non-
prostanoid prostacyclin receptor agonists, and inhaled vasoactive
intestinal peptide. The efﬁcacy of these new compounds needs
to be demonstrated ‘on top of’ the available approved PAH drug
therapies in order to avoid any delay in the initiation of effective
medications. Therefore, a combination approach is required also
in this case.
Future study designs
The future decisive challenge is the identiﬁcation of the most
appropriate study designs to demonstrate the efﬁcacy-to-safety
ratio of combination strategies either with already approved
drugs or with novel therapies. The replication of the traditional
phase III strategy (placebo-controlled design in treatment-naı ¨ve
patients, 6MWT as primary endpoint assessed after 3–4 months
of treatment) appears not to be suitable for practical and ethical
reasons. In fact, the inclusion of patients on background effective
therapies will reduce our ability to demonstrate a difference
between the ‘placebo-treated group’ and the ‘actively treated
group’, in particular, if exercise capacity is the primary endpoint.
This phenomenon was observed in the more recently completed
RCTs in which the treatment effect on the 6MWT ranged from
15 to 25 m
16,18,19,26 when compared with the traditional 35 to
55 m observed in historical monotherapy studies. A possible sol-
ution is the adoption of different primary endpoints, such as
TtCW, accepted by the regulatory agencies. This approach also
presents challenges, including the objective and uniform deﬁnition
of this composite endpoint and the sample size and/or duration of
the study, which can be either pre-speciﬁed or based on the
number of observed events. Additional problems of multicentre
and international studies are linked to the country-related hetero-
geneity of the PAH-approved medications, the different attitudes
for hospitalization in different geographic areas, and the availability
of centres with experience in combination therapy.
Initial appropriate answers to solve these difﬁculties have been
given by the regulatory agencies and by the investigators. In fact,
in the recently published ‘Guideline on the Clinical Investigations
of Medicinal Products for the Treatment of PAH’,
28 the Commit-
tee for Medicinal Products for Human Use (CHMP) of the EMA
clariﬁed the requirements for the approval of PAH medications,
indicating the characteristics of acceptable primary endpoints,
including 6MWT and TtCW. Randomized controlled trials adopt-
ing novel designs and TtCW as primary endpoint have already
been initiated. For example, a morbidity and mortality primary end-
point has been adopted in the SERAPHIN study (Study with
Endothelin Receptor Antagonist in Pulmonary arterial Hyperten-
sion to Improve cliNical outcome), testing the efﬁcacy of a new tis-
sular dual endothelin receptor antagonist, and in the AMBITION
study (A randomized, double-blind, placebo-controlled, multicen-
tre study of ﬁrst-line combination therapy with AMBrIsentan and
Tadalaﬁl vs. monotherapy in subjects with pulmonary arterial
hypertensION), testing the efﬁcacy of the initial combination
therapy of a selective endothelin receptor antagonist and a phos-
phodiesterase type-5 inhibitor when compared with monotherapy
using single compounds.
Pulmonary arterial hypertension 2085Conclusions
In conclusion, the clear recent progress in the treatment of PAH
supported by the concordant results of recent meta-analyses
need to be further extended because the current treatment strat-
egy is still not satisfactory. This requires a joint effort between
regulatory agencies, patient associations, investigators, and industry
for the development and completion of additional new RCTs.
There is no time for sterile discussions about the extent of
current achievements based on others’ published papers. Let us
ﬁght the battle against PAH ‘on the ﬁeld’ together. Our patients
deserve this commitment.
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